The present invention relates to 2- [1-phenyl-5-hydroxy-4-alpha-methylhexahydrocyclopenta [f] indazol-5-yl] ethylphenyl derivatives as glucocorticoid receptor ligands, which are useful in the treatment of a number of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also contemplated.